Free Trial
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Oncolytics Biotech logo
$1.03 -0.09 (-8.04%)
(As of 11/13/2024 ET)

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Key Stats

Today's Range
$1.01
$1.10
50-Day Range
$0.85
$1.40
52-Week Range
$0.84
$1.75
Volume
606,553 shs
Average Volume
327,561 shs
Market Capitalization
$79.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
30th Percentile Overall Score

ONCY MarketRank™: 

Oncolytics Biotech scored higher than 30% of companies evaluated by MarketBeat, and ranked 840th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oncolytics Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.29) to ($0.32) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncolytics Biotech has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oncolytics Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    3.65% of the outstanding shares of Oncolytics Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Oncolytics Biotech has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oncolytics Biotech has recently increased by 6.04%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncolytics Biotech does not currently pay a dividend.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.65% of the outstanding shares of Oncolytics Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Oncolytics Biotech has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Oncolytics Biotech has recently increased by 6.04%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oncolytics Biotech has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.
  • Search Interest

    Only 8 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 6.82% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONCY Stock News Headlines

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Oncolytics Biotech Reports Promising Cancer Treatment Results
Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
See More Headlines

ONCY Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY stock has decreased by 23.7% and is now trading at $1.03.
View the best growth stocks for 2024 here
.

Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings data on Friday, November, 3rd. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.03.

Top institutional shareholders of Oncolytics Biotech include International Assets Investment Management LLC (0.23%).

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Meta Platforms (META), Palantir Technologies (PLTR), QUALCOMM (QCOM) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
11/03/2023
Today
11/13/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCY
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+288.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
76,997,000
Market Cap
$79.38 million
Optionable
Not Optionable
Beta
1.69
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:ONCY) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners